VITAL Corporation to distribute Imagine Eyes’ rtx1™ Adaptive Optics Retinal Camera in Japan where the device has recently gained Shonin regulatory approval

Orsay France and Tokyo Japan, October 26, 2012 – Imagine Eyes, the pioneer in cellular-level retinal imaging, and VITAL Corporation, a leading Japanese distributor of advanced medical devices, are proud to announce that VITAL will distribute Imagine Eyes’ rtx1™ Adaptive Optics Retinal Camera* in Japan.

“VITAL has a proud history of identifying novel medical technologies that benefit doctors and patients alike” states Masao Ichinoseki, President of VITAL Corporation. “Imagine Eyes’ retinal camera recently received Shonin (NINSHO) approval from the Japanese Ministry of Health, Labor and Welfare and can now enable Japanese ophthalmologists to visualize their patients’ retinas in unparalleled detail. We hope that this will allow them to enhance the quality of care they provide and help them save vision.”

“Japan is the world’s second largest market for medical devices after the United States” remarks Tomoki Tateishi, Marketing Director at VITAL Corporation. “Historically, VITAL uses an effective strategy based in part on inviting leading experts in their field to come and present their experience with the cutting-edge medical devices we supply especially in interventional cardiology and cardiovascular surgery. We will use a similar approach as part of marketing the rtx1 Adaptive Optics Retinal Camera in Japan and we expect to see rapid adoption by ophthalmologists across the country. The first such event will be held on October 26, 2012, and will spotlight the work of both French and Japanese researchers that use the rtx1.”

“Several leading Japanese researchers embraced the rtx1’s cellular-level-retinal-imaging abilities very early on, and we are very thankful to them for their support as it has been instrumental in creating demand in their country” says Nicolas Chateau, Imagine Eyes’ Co-founder and CEO. “We look forward to working with VITAL to provide Japanese ophthalmologists with a new tool that will help further sight-saving research today and potentially improve the already impressive healthcare citizens receive in the future.”

VITAL will be providing demonstrations of the rtx1 Adaptive Optics Retinal Camera in room E at the 66th Annual Japanese Clinical Ophthalmology Congress in Kyoto Japan from October 25-28, 2012. For more information, about Imagine Eyes, please visit www.imagine-eyes.com, or contact Mark Zacharria on +33 (0)1 64 86 15 66 or by e-mail at www.imagine-eyes.com/contact. For information about VITAL, the rtx1 in Japan or the symposium on October 26, 2012, please visit www.vital-j.co.jp, or contact Tomoki Tateishi on +81 (3) 3458-1261 or by e-mail at t.tateishi@vital-j.co.jp.

About Imagine Eyes – Imagine Eyes develops ophthalmic instruments that analyze the eye at the microscopic scale. Conceived from a revolutionary technology, adaptive optics, its products enable cellular-level retinal imaging, precision measurement of the eyes’ refractive errors and vision simulation. Founded in 2003 in Orsay, France by photonics and ophthalmic industry specialists, the company is ISO 9001 and 13485 certified. It maintains its position as a technology leader thanks to its intensive R&D program, broad portfolio of patents and the marketing of cutting-edge products that have been rapidly adopted by its customers.

About Vital Corporation: Since 1984, Vital has been a distributor of advanced medical devices to primary hospitals all across Japan. By gathering a wealth of knowledge in the state of the art technology, the company has established lasting credibility with hospitals and doctors by continuously providing them with top-quality service and 24-hour support. In recent years, Vital has focused on developing minimally invasive surgical devices and vascular imaging tools with the hope of minimizing patients’ physical and mental strain, and will continue to strive for the development of medical technology.

* Important notice – The rtx1 is available outside of the European Union and Japan for use as a Research Use Only device where such use is authorized by local governing regulations.